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ABSTRACT
Wnt signaling is implicated in bone formation and activated in breast cancer cells 
promoting primary and metastatic tumor growth. A compelling question is whether 
osteogenic miRNAs that increase Wnt activity for bone formation are aberrantly 
expressed in breast tumor cells to support metastatic bone disease. Here we report 
that miR-218-5p is highly expressed in bone metastases from breast cancer patients, 
but is not detected in normal mammary epithelial cells. Furthermore, inhibition of 
miR-218-5p impaired the growth of bone metastatic MDA-MB-231 cells in the bone 
microenvironment in vivo. These findings indicate a positive role for miR-218-5p 
in bone metastasis. Bioinformatic and biochemical analyses revealed a positive 
correlation between aberrant miR-218-5p expression and activation of Wnt signaling 
in breast cancer cells. Mechanistically, miR-218-5p targets the Wnt inhibitors 
Sclerostin (SOST) and sFRP-2, which highly enhances Wnt signaling. In contrast, 
delivery of antimiR-218-5p decreased Wnt activity and the expression of metastasis-
related genes, including bone sialoprotein (BSP/IBSP), osteopontin (OPN/SPP1) and 
CXCR-4, implicating a Wnt/miR-218-5p regulatory network in bone metastatic breast 
cancer. Furthermore, miR-218-5p also mediates the Wnt-dependent up-regulation of 
PTHrP, a key cytokine promoting cancer-induced osteolysis. Antagonizing miR-218-
5p reduced the expression of PTHrP and Rankl, inhibited osteoclast differentiation in 
vitro and in vivo, and prevented the development of osteolytic lesions in a preclinical 
metastasis model. We conclude that pathological elevation of miR-218-5p in breast 
cancer cells activates Wnt signaling to enhance metastatic properties of breast cancer 
cells and cancer-induced osteolytic disease, suggesting that miR-218-5p could be an 
attractive therapeutic target for preventing disease progression.
INTRODUCTION
Breast cancer is among the most prevalent 
malignancies worldwide, constituting a tremendous 
medical and socio-economic problem [1]. After initial 
treatment distant metastases frequently occur after years 
or even decades of a disease-free survival [2]. Bone is a 
primary site for breast cancer metastases and about 70% of 
breast cancer patients at an advanced stage of the disease 
suffer from osteolytic bone metastases, a stage at which 
the disease is incurable [2]. Osteolytic metastases are 
often associated with debilitating bone pain and skeletal-
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related events (SREs), including pathological fractures. 
Currently, patients are treated with anti-resorptive drugs 
(bisphosphonates or denosumab, a monoclonal antibody 
against the Receptor activator of nuclear factor kappa-B 
ligand (RANKL)) that restrict the progression of bone 
destruction and increase survival [3]. However, novel 
therapeutic targets are needed for intervention prior to 
bone metastasis.
Bone metastases perturb the physiological 
maintenance of bone mass and bone remodeling by the 
coordinated activities of matrix-producing osteoblasts 
and bone-resorbing osteoclasts. Cancer cells produce 
growth factors such as Parathyroid hormone-related 
protein (PTHrP), which stimulate osteoblasts to secrete 
RANKL and other bone–resorbing cytokines [4]. 
RANKL increases osteoclast activity and subsequent 
bone degradation during which matrix-derived growth 
factors, e.g. Transforming Growth Factor-β1 (TGF-β1), 
are released into the metastatic micro-environment. These 
factors further stimulate cancer cell proliferation creating a 
‘vicious cycle’, a multi-directional process that perpetuates 
metastatic bone destruction [5].
Small non-coding microRNAs (miRNAs) have 
established functions in both carcinogenesis and bone 
remodeling [6–8]. A large pool of evidence suggests that 
miRNAs are potential targets for therapeutic intervention 
of cancer [9, 11, 12]. By silencing the expression of 
hundreds of genes simultaneously, a single miRNA can act 
as an epigenetic master regulator of important biological 
processes. Deregulation of the miRNA-dependent control 
also contributes to oncogenesis and leads to the loss of 
tumor suppressors and upregulation of oncogenes, thus 
ultimately driving tumor progression and metastasis 
[9, 12]. Global profiling and genome wide sequencing 
have identified transcription factors and miRNAs 
that are deregulated in tumor cells [13]. For example, 
compromised control of epithelial-mesenchymal transition 
(EMT) and mesenchymal-epithelial transition (MET) by 
perturbation of miRNA-transcription factor networks is 
well documented in cancer progression [14]. Furthermore, 
abnormal expression of the bone-specific transcription 
factor Runx2 in bone metastatic cells [15] is in part due 
to the loss of two miRNAs targeting Runx2 and the BMP 
pathway [16]. Thus, while supporting normal development 
of tissues, miRNAs also mediate the progression of 
metastatic bone disease [11].
Wnt signaling represents another important 
pathway that regulates normal tissue formation, as 
well as contributes to tumor onset and progression [17, 
18]. Osteogenesis is highly dependent on the presence 
of Wnt activators and the absence of Wnt inhibitors 
[19]. miR-218 was previously characterized to promote 
bone formation by osteoblasts through upregulation of 
Wnt signaling [20]. Here, we investigated functional 
consequences of high levels of miR-218-5p in breast 
cancer cells. We hypothesized that aberrant miR-218-
5p expression would induce the osteomimetic properties 
of breast cancer cells and cause aggressive metastatic 
bone disease. Our cellular and in vivo studies revealed 
a positive correlation of miR-218-5p expression and 
β-catenin signaling in bone metastases and demonstrate 
that miR-218-5p targets two inhibitors of Wnt signaling, 
sclerostin (SOST) and secreted frizzled-related protein 
2 (SFRP2). Furthermore, we show a striking inhibition 
of tumor growth in the bone and a reduced osteolytic 
disease with antimiR-218-5p blockade of Wnt–
dependent activation of genes related to both metastasis 
and osteolysis and elucidated the underlying mechanism 
of antimiR-218-5p in bone metastatic breast tumors. 
In response to antimiR-218-5p, tumor growth in the 
bone marrow microenvironment and the accompanying 
metastatic bone disease was largely inhibited. These 
findings may have translational potential for therapeutic 
intervention to reduce bone metastasis by inhibiting 
miR-218-5p in breast cancer cells.
RESULTS
miR-218-5p is increased in bone metastases and 
promotes breast cancer cell proliferation
To investigate the relevance of miR-218-5p in the 
context of bone metastases in humans, we examined 
the expression of miR-218-5p in healthy bone, primary 
breast cancer and bone metastases obtained from breast 
cancer patients. H&E staining and immunohistochemical 
analysis confirmed that all samples of metastatic tissue 
consisted of actively proliferating breast cancer cells 
(Figure 1A). As expected from previous studies [20], miR-
218-5p was detected in healthy control bone (Figure 1B). 
Similarly, miR-218-5p was expressed in primary breast 
tumors, however, expression strikingly increased in bone 
metastases (Figure 1B). This finding was consistent with in 
vitro expression analysis of miR-218-5p in several breast 
cancer cell lines (Figure 1C). Expression of miR-218-5p 
was low in non-malignant, ER- epithelial MCF-10A cells 
and in early-stage, non-metastatic ER+ MCF-7 breast 
cancer cells and significantly increased in two sublines 
of ER- metastatic MDA-MB-231 breast cancer cells that 
grow aggressively in bone (Figure 1C). To confirm that 
miR-218 is linked to bone metastatic capacity rather than 
hormone-receptor status, expression was examined in 
the ER-negative MCF10 series of cell lines [21, 28, 29]. 
miR-218-5p expression was increased in pre-malignant 
MCF-10AT1 cells compared to non-malignant epithelial 
MCF-10A cells (Supplementary Figure S1). Importantly, 
expression was further increased in MCF10CA1 cells, 
which have the ability to metastasize and grow in bone 
[22]. The specific high abundance of miR-218-5p in 
bone metastases in patients and bone metastatic breast 
cancer cells suggests that miR-218-5p contributes to the 
aggressive properties of metastatic breast cancer cells.
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To functionally test this hypothesis, we modulated 
miR-218-5p levels in MDA-MB-231 cells by stable 
overexpression or inhibition of miR-218-5p using 
lentiviral vectors containing Green Fluorescent Protein 
(GFP; Supplementary Figure S2A). In addition, because 
viral-free delivery of small RNAs is more relevant for 
future translational applications, we tested the mechanistic 
function of miR-218-5p in breast cancer cells using a 
synthetic miR-218-5p mimic, inhibitor, and non-targeting 
control oligonucleotides (Supplementary Figure S2B). 
Delivery of miR-218-5p mimic significantly increased 
breast cancer cell proliferation while antagonizing miR-
218-5p resulted in a reduced growth of metastatic cancer 
cells in vitro (Figure 1D). These results were corroborated 
by forced expression of miR-218-5p or its corresponding 
antimiR-218-5p in MDA-MB-231 cells (Supplementary 
Figure S2C). However, neither delivery nor forced 
expression of miR-218-5p mimic or inhibitor affected 
cell migration or invasion (Supplementary Figure S3A, 
S3B). These data suggest that miR-218-5p specifically 
supports cell proliferation and metastatic tumor growth in 
metastatic breast cancer cells.
Figure 1: miR-218-5p is elevated in bone metastases. A. H&E staining (upper panel) and immunohistochemical analysis of the 
proliferation marker Ki-67 (lower panel) in bone metastases from breast cancer patients. Scale bar indicates 50 μm. B. Expression of 
miR-218-5p was determined in healthy human bone (white bars), primary breast tumors (light grey bars) and bone metastasis biopsies 
obtained from breast cancer patients (dark grey bars) by qRT-PCR. C. miR-218-5p expression was analyzed in non-malignant epithelial 
MCF-10A cells, non-metastatic MCF-7 breast cancer cells and in two sub clones of metastatic MDA-MB-231 breast cancer cells by qRT-
PCR. N= 4 independent experiments. Mean values ± SEM, * p<0.05, *** p<0.001 vs. MCF-10A. D. Cell proliferation was determined in 
MDA-MB-231 cells after transfection with miR-218-5p, antimiR-218-5p, or non-targeting control (miR-Ctrl) using an MTS Assay. N= 4 
independent experiments. Mean values ± SEM, * p<0.05 vs. miR-Ctrl.
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AntimiR-218-5p treatment reduces tumor 
growth in the bone marrow environment and 
protects bone from breast cancer-induced 
osteolytic disease
To translate the in vitro findings into a preclinical 
model of osteolytic disease, we transfected MDA-MB-231 
cells stably expressing luciferase (MDA-MB-231-Luc) 
with miR-218-5p mimic, antimiR-218-5p inhibitor, or 
the non-targeting control and injected tumor cells into 
the tibiae of immunocompromised SCID mice. Weekly 
bioluminescence imaging documented a significant 
increase in tumor growth when miR-218-5p mimic was 
delivered in MDA-MB-231-luc cells. In striking contrast, 
antimiR-218-5p reduced tumor growth in the bone marrow 
microenvironment (Figure 2A, 2B, Supplementary Figure 
S4). Supporting these observations, the number of actively 
proliferating tumor cells greatly increased by miR-218-
5p while antagonizing miR-218-5p significantly impaired 
breast cancer cell proliferation in vivo (Figure 2C). 
Intratibial tumor growth was accompanied with increased 
osteoclast activity and bone resorption in the presence of 
miR-218-5p as demonstrated by intense TRAP staining 
in the bone-tumor interface (Figure 2D). Inhibiting 
miR-218-5p was highly effective in reducing osteoclast 
resorptive activity (Figure 2D) and provided protection 
from the development of osteolytic lesions as determined 
by μCT analysis (Figure 2E, 2F). Although the majority 
of the mice in all groups developed lung metastases (miR-
Ctrl: 5/6, miR-218-5p: 6/6, antimiR-218-5p: 4/6 mice), 
antagonizing miR-218-5p reduced number and size of 
metastatic nodules in the lung thereby attenuating the 
overall metastatic burden (Supplementary Figure S5A-
S5D). These data indicate that inhibition of miR-218-5p 
blocks the vicious cycle of osteolytic bone disease and the 
accompanying metastasis.
Wnt signaling is enriched in miR-218-5p targets 
and activated in bone metastases
To understand the underlying molecular mechanism 
of miR-218-5p in bone-metastatic breast cancer, we 
investigated the biological functions and pathways 
regulated by miR-218-5p. Using Ingenuity Pathway 
Analysis (IPA – www.ingenuity.com), 967 genes were 
identified as predicted or experimentally validated 
downstream targets of miR-218-5p. These 967 miR-
218-5p target genes were significantly enriched for 
(p < 0.05) above normal genomic distribution in 116 
Ingenuity canonical pathways. The essential bone-related 
pathways of Wnt/β-catenin signaling and RANK signaling 
in osteoclasts were identified in our analysis with 19 
and 9 genes, respectively, being miR-218-5p targets 
(Figure 3A-3C).
Because Wnt signaling was highly enriched for in 
miR-218-5p targeted pathways and is tightly linked to 
breast cancer growth [30], we investigated the connection 
between Wnt signaling and miR-218-5p in bone 
metastases. Immunohistochemical staining of patient-
derived bone metastasis biopsies revealed strong β-catenin 
staining in the nuclei of breast cancer cells (Figure 
3D), supporting active engagement of Wnt signaling in 
proliferating bone metastases, which also highly express 
miR-218-5p (Figure 1A, 1B). In addition, Wnt signaling 
activity was significantly increased in metastatic MDA-
MB-231 cells, which highly express miR-218-5p (Figure 
1C) as demonstrated by the activity of the Wnt responsive 
TopFlash reporter and expression of Wnt target genes 
CyclinD1, LEF1 and TCF4 (Figure 3E, 3F). These results 
strongly suggest that miR-218-5p and Wnt signaling are 
connected in bone metastases.
miR-218-5p and antimiR-218-5p regulate 
Wnt signaling through direct targeting of Wnt 
inhibitors with effects on cell proliferation
We further examined the Wnt-miR-218-5p axis 
and direct miR-218-5p targets in breast cancer cells 
by focusing on Wnt inhibitors previously shown to be 
controlled by miR-218-5p in osteoblasts [20]. Consistent 
with results observed in osteoblasts, we found that the 
miR-218-5p reduced the expression of the endogenous 
sFRP2 whereas the antimiR-218-5p increased the 
expression level (Figure 4A). Furthermore, in metastatic 
cells, miR-218-5p downregulated Sclerostin expression, 
that was reversed by delivery of antimiR-218-5p (Figure 
4A). Because the default activity of miRNAs is to repress 
protein translation by binding to the 3’UTR of mRNAs, 
we assessed whether miR-218-5p directly binds to SFRP2 
and SOST using the 3’UTR reporter assays. Ectopic miR-
218-5p significantly down-regulated luciferase activity of 
both SFRP2 and SOST 3’UTRs in MDA-MB-231 cells 
(Figure 4B), while antimiR-218-5p increased luciferase 
activity via the 3’UTR of SFRP2 and SOST (Figure 4B). 
The regulation was blunted when the miR-218-5p binding 
sites in each of the potential target UTRs were mutated 
(Figure 4B). These findings indicate that the 3’UTRs of 
SOST and SFRP2 are directly targeted by miR-218-5p to 
suppress their expression in metastatic breast cancer cells.
Stimulation of Wnt-signaling is predicted to activate 
the canonical Wnt responsive gene CyclinD1, which 
promotes breast cancer proliferation as well as LEF1 
and TCF4, which are transcriptional mediators of the 
Wnt pathway. Indeed, CyclinD1, LEF1 and TCF4 were 
significantly increased in response to miR-218-5p delivery 
and decreased upon inhibition of miR-218-5p (Figure 4C). 
Furthermore, delivery of synthetic antimiR-218-5p oligos 
or lentivirus-mediated forced expression of antimiR-218-
5p reduced Wnt signaling activity compared to control as 
shown by TopFlash assays that quantify Wnt-responsive 
promoter activity (Figure 4D, Supplementary Figure S6A). 
We also examined functional inhibition of Wnt signaling 
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Figure 2: AntimiR-218-5p treatment reduces tumor growth and protects from breast cancer-induced osteolytic 
disease. A. MDA-MB-231 cells stably expressing luciferase were transfected with the indicated oligonucleotide and transplanted into 
the tibiae of immunocompromised mice. Tumor growth was visualized after four weeks by bioluminescence imaging. B. Quantification of 
bioluminescence intensity (BLI) using Living Image software. N= 6 mice/ group. Mean values ± SEM, * p<0.05 vs. miR-Ctrl. C. Actively 
proliferating cancer cells were stained with Ki-67 and quantified with the Osteomeasure System. Scale bar indicates 50 μm. Number of 
Ki-67-positive cells/ field is indicated below each representative image. N= 6 mice/ group. Mean values ± SEM, * p<0.05 vs. miR-Ctrl. 
D. Presence of active osteoclasts in tumor bearing bones following miR-218-5p deregulation was visualized by TRAP staining. Scale bar 
indicates 50 μm. E. Osteolytic lesions were determined by μCT imaging and F. analysis of bone mass. BV/TV; bone volume/tissue volume. 
N= 6 mice/ group. Mean values ± SEM, * p<0.05 vs. miR-Ctrl.
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Figure 3: Wnt and RANK signaling were among the highest enriched pathways of miR-218-5p target genes. A-C. 
Predicted and validated miR-218-5p targets, highlighted in red, are depicted in bone-related pathways. 116 Ingenuity canonical pathways 
were enriched over normal genomic distribution for the 967 downstream targets of miR-218-5p (p < 0.05). A. Target genes within the Wnt/
β-Catenin signaling and RANK signaling in osteoclasts pathways are listed. The interaction partners and molecular mechanisms of these 
miR-218-5p target genes are depicted within the Wnt/β-Catenin signaling B. and RANK signaling C. pathways. ‡ SOST is not included in 
the Ingenuity Canonical Pathway Wnt/β-Catenin signaling and is not used to calculate the p-value in Figure 3A. SOST is well established 
to inhibit LRP5 [46]. D. Immunohistochemical analysis of β-catenin in bone metastasis biopsies. Scale bar indicates 100 μm (upper panel) 
and 50 μm (lower panel). E. Wnt signaling activity was determined by TopFlash assay in MCF-10A, MCF-7 and MDA-MB-231 cells. N= 
3 independent experiments. F. Expression of Wnt target genes CyclinD1, LEF1 and TCF4 was analyzed by qRT-PCR and normalized to 
GAPDH expression. N= 3 independent experiments. Mean values ± SEM, * p<0.05 vs. MCF-10A.
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Figure 4: miR-218-5p directly targets Wnt inhibitors to augment Wnt signaling. A. Gene expression analysis of Wnt 
inhibitors upon transfection with miR-218-5p or antimiR-218-5p oligonucleotides. Mean values ± SEM, * p<0.05 vs. miR-Ctrl. B. 3’UTR 
Luciferase assay was used to determine the direct binding between miR-218-5p and the 3’UTR of SFRP2 or SOST (wt). The miR-218-5p 
target site (red letters) was mutated to alleviate binding. Mean values ± SEM, * p<0.05 vs. miR-Ctrl. C. Expression of the Wnt target genes 
CyclinD1, LEF1 and TCF4 was analyzed by qRT-PCR upon transfection with indicated oligonucleotides. Mean values ± SEM, * p<0.05 
vs. miR-Ctrl. D. TopFlash luciferase assay to determine Wnt signaling activity in MDA-MB-231 cells after transfection with miR-218-5p 
or antimiR-218-5p oligonucleotides. Mean values ± SEM, * p<0.05 vs. miR-Ctrl. E. MTS cell proliferation assay of breast cancer cells 
transfected with miR-218-5p or antimiR-218-5p oligonucleotides. Wnt signaling was inhibited by a small molecule inhibitor CCT036477 
(Wnt inh) or activated using Lithium Chloride (LiCl). GAPDH expression was used for qRT-PCR normalization. Mean values ± SEM, * 
p<0.05 vs. miR-Ctrl. N= 3-4 independent experiments.
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using a small molecule inhibitor, CCT036477, which 
reduced miR-218-5p –induced proliferation in MDA-
MB-231 cells (Figure 4E). Furthermore, Wnt signaling 
activation by LiCl restored cell growth in antimiR-218-
5p treated breast cancer cells (Figure 4E). Collectively, 
these data establish a functional relationship between Wnt 
signaling, miR-218-5p and breast cancer cell proliferation 
to promote tumor growth.
Inhibition of miR-218-5p in breast cancer cells 
reduces Rankl expression in osteoblasts and 
impairs osteoclast differentiation
To better understand the anti-osteolytic function of 
miR-218-5p inhibition downstream of Wnt signaling, we 
performed gene expression analysis of Wnt-target genes 
related to bone metastasis and osteolysis. AntimiR-218-
5p diminished the expression of several genes associated 
with bone metastasis and osteoclast activation, including 
osteopontin (OPN/SPP1), bone sialoprotein (BSP/IBSP), 
C-X-C chemokine receptor type 4 (CXCR4), and PTHrP/
PTHLH (Supplementary Figure S6B), suggesting that 
antimiR-218-5p suppresses the osteomimetic properties 
of metastatic breast cancer cells.
Since PTHrP is a well-established key cytokine 
promoting breast cancer-induced bone resorption and a 
recently identified Wnt target gene [4, 25], we focused on 
PTHrP as a novel cancer-related downstream effector of 
miR-218-5p. Immunohistochemical staining confirmed 
that PTHrP is highly expressed in bone metastases (Figure 
5A). Functionally, miR-218-5p increased the expression 
of PTHrP in MDA-MB-231 cells, which was reduced 
upon Wnt inhibition (Figure 5B). Activation of Wnt 
signaling restored PTHrP expression in antimiR-218-5p 
treated cells, indicating Wnt-dependent regulation (Figure 
5C). Given that PTHrP activates osteoclasts by inducing 
Rankl expression in osteoblasts, we collected conditioned 
medium (CM) from MDA-MB-231 cells transfected with 
miR-218-5p or antimiR-218-5p and measured the level 
of secreted PTHrP. Consistent with an activated gene 
expression, PTHrP protein concentration was increased 
in the CM upon miR-218-5p delivery and reduced when 
miR-218-5p was antagonized (Figure 5D). In support of 
our hypothesis, CM from cells delivered with miR-218-
5p increased Rankl expression in long bone osteoblasts 
whereas Rankl expression was strikingly decreased when 
osteoblasts were cultured with CM from antimiR-218-5p-
transfected breast cancer cells (Figure 5E). Consequently, 
CM from antimiR-218-5p treated cells reduced osteoclast 
differentiation in an osteoblast-osteoclast co-culture system 
as shown by the decreased TRAP staining and the reduced 
number of multinucleated cells (Figure 5F, 5G). These data 
suggest that antagonizing miR-218-5p in metastatic breast 
cancer cells impairs the osteolytic signaling cascades 
between breast cancer cells, osteoblasts and osteoclasts, 
which results in reduced osteolytic burden in vivo.
Together, our findings indicate that miR-218-5p 
is elevated in bone metastases and directly targets Wnt 
signaling inhibitors to increase Wnt signaling activity 
and promote breast cancer cell proliferation (Figure 5H). 
Furthermore, miR-218-5p increases the expression of 
PTHrP, resulting in an increased expression of Rankl in 
osteoblasts, an enhanced osteoclast differentiation and 
activated bone resorption. Importantly, antimiR-218-
5p reverses these effects by reducing Wnt activity and 
expression of both PTHrP and Rankl, thereby attenuating 
the oncogenic and osteolytic properties of metastatic 
breast cancer cells.
DISCUSSION
Our novel finding that miR-218-5p expression 
is significantly elevated in breast cancer cells that 
metastasize to bone provides strong support for a 
component of biological control that goes beyond 
regulation by transcription factors. Our results reinforce 
the concept that post-transcriptional miRNA regulators are 
aberrantly expressed in tumor progression and metastasis 
[10]. Moreover, our results indicate that the miR-218-
5p-Wnt regulatory loop significantly contributes to the 
osteomimetic and metastatic properties of bone metastatic 
breast cancer cells. Abundance of miR-218-5p in MDA-
MB-231 cells parallels function that mediated biological 
control in osteoblasts to increase Wnt signaling and 
expression of osteoblast related genes [20]. This finding 
suggests that miR-218-5p, which is highly expressed in 
bone metastases biopsies and metastatic cancer cells, 
may be a component of bone tumor growth and the 
accompanying osteolytic disease in patients. Related to 
this role of miR-218-5p, we found that antimiR-218-5p 
reduces expression of genes associated with osteolytic 
properties of cancer cells in bone, osteoclast activation 
and development of osteolytic lesions in mice. This 
finding positions antimiR-218-5p treatment as a potential 
novel therapeutic concept to limit breast cancer-induced 
osteolytic disease.
Elevated miR-218-5p expression has previously 
been associated with estrogen receptor- positive breast 
tumors indicating a possible role in certain breast cancer 
phenotypes [31]. Furthermore, elevated miR-218-5p 
expression is a promising diagnostic and prognostic 
biomarker of human chondrosarcoma [32]. In contrast, 
during early osteosarcoma miR-218-5p is down-regulated 
[33] and in other cancers miR-218-5p was reported to 
function as a tumor suppressor through regulation of 
the Slit-Robo pathway [34]. While Slit2 is expressed 
in metastatic breast cancer cells, it is associated with 
metastasis to brain but not to bone [35] whereas both 
estrogen and Wnt signaling are linked to bone metastasis 
[36]. In particular, Wnt signaling influences bone 
metastasis through autocrine mechanisms affecting 
processes that include survival and proliferation, 
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Figure 5: Inhibition of miR-218-5p in breast cancer cells decreases PTHrP expression, reduces Rankl in osteoblasts 
and impairs osteoclast differentiation. A. PTHrP expression in bone metastases was determined by immunohistochemistry. Scale bar 
indicates 100 μm (upper panel) and 50 μm (lower panel). B. PTHrP mRNA expression was analyzed in MDA-MB-231 cells delivered with 
miR-218-5p upon inhibition of Wnt signaling using a small molecule inhibitor CCT036477. C. Cells were transfected with antimiR-218-5p 
and Wnt signaling was activated by Lithium Chloride. PTHrP mRNA expression was determined by qRT-PCR. D. Conditioned medium 
(CM) was collected from MDA-MB-231 cells transfected with miR-218-5p mimic or inhibitor and PTHrP protein level was determined 
using ELISA. E. Long bone osteoblasts were incubated with CM collected from miR-218-5p mimic or inhibitor -delivered MDA-MB-231 
cells. Rankl expression was determined in osteoblasts by qRT-PCR. F. Osteoblast-osteoclast co-cultures were performed in the presence 
of CM from MDA-MB-231 cells transfected with miR-218-5p or antimiR-218-5p. G. Osteoclasts were stained with TRAP and TRAP-
positive multinucleated cells (MNCs) were counted. H. Model of miR-218 function in the metastatic bone environment. Minimum of 3 
independent experiments. Mean values ± SEM, *p<0.05, ** p < 0.01 vs. miR-Ctrl.
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and paracrine mechanisms by modulating the bone 
microenvironment for efficient colonization and outgrowth 
of tumor cells [25, 37]. It is appreciated that the power of 
miRNAs in regulating biological processes in a temporal-
spatial manner is influenced by the cellular environment 
and the activity of signaling pathways. For example, 
miRNAs can act as tumor suppressors or oncogenes 
depending on the cellular context and cell specific 
signaling pathways and targets [9, 12]. This functional 
ambivalence is understandable in view of the roles of 
miRNAs in feed-back and feed-forward mechanisms that 
control normal developmental signaling pathways. Our 
findings suggest that regulation of Wnt signaling, which is 
an important pathway in bone metastasis, is a prominent 
mechanism for miR-218-5p in breast cancer metastasis.
Although other miRNAs have been identified in 
regulating Wnt signaling and miR-218 has been associated 
with other cancers, our study defines a unique functional 
activity of miR-218-5p in promoting metastatic tumor 
growth of triple negative breast cancer cells in bone 
and further exacerbating the osteolytic bone disease. 
miR-218-5p directly downregulates two Wnt inhibitors 
accompanied by increased Wnt activity and markedly 
elevated expression of Wnt target genes CyclinD1, LEF1 
and TCF4. These novel findings are consistent with 
clinical observations. For example, high expression of 
CyclinD1 predicts for poor prognosis in breast cancer 
patients [38]. Functionally, CyclinD1 enhances cell 
proliferation [39]. Thus, the cell-autonomous impairment 
of proliferation by antimiR-218-5p may be due to 
downregulation of CyclinD1. Importantly, more prominent 
differences were observed in tumor growth and cancer cell 
proliferation in vivo, suggesting additional mechanisms at 
play. Indeed, several metastasis-related genes were down-
regulated upon inhibition of miR-218-5p in breast cancer 
cells, including CXCR4, a crucial cytokine supporting 
breast cancer homing to and growth in bone supporting 
the importance of antimiR-218-5p in impairing breast 
cancer growth in the bone environment [40]. For example, 
antimiR-218-5p impaired cancer-induced bone destruction 
thereby reducing the release of several growth factors from 
the bone environment upon cancer-induced osteolysis 
which consequently supports the vicious cycle of tumor 
growth [3, 4]. Thus both the cell-autonomous and bone 
environment-mediated mechanisms contribute to reduced 
tumor growth by antimiR-218.
Breast cancer cells exhibit properties of osteoblast, 
reflected by expression of bone matrix proteins, a process 
referred as osteomimicry. BSP and OPN are prominent, 
mineral-associated proteins in the extracellular matrix of 
bone that have been implicated in the metastatic activity 
of cancer cells and that may have a role in targeting 
metastatic cells to bone [41]. Interestingly, antimiR-
218-5p decreased the expression of both BSP/IBSP 
and OPN/SPP1. Thus, the miR-218-5p/Wnt axis may 
support osteomimicry of bone metastatic breast cancer 
cells by promoting expression of osteoblast-related ECM 
proteins and paracrine factors under normal physiological 
conditions in osteoblasts (i.e., during skeletal development 
and early bone formation) and under pathological 
conditions in metastatic breast cancer cells (i.e., in adult 
patients which homeostatically regulate bone mass). 
Beyond its function in osteoblasts, miR-218-5p is required 
for normal development of several additional cell types 
that include motor neurons [42, 43]. Although we did not 
observe obvious side-effects of miR-218-5p in vivo, it 
cannot be excluded that systemic inhibition of miR-218-
5p can cause adverse effects in other tissues. Therefore, it 
will be important in the future to investigate novel tools to 
target delivery of small RNA specifically to tumor cells.
Progression of breast cancer to the stage of bone 
metastasis has a devastating clinical outcome. PTHrP is 
a key cytokine secreted from tumor cells that promotes 
metastatic bone destruction by activating osteoclasts. 
Recently, activation of Wnt signaling in metastatic 
breast cancer cells was shown to induce expression 
of PTHrP through the Gli1 transcription factor [25]. 
Our findings link miR-218-5p with the Wnt-PTHrP 
cascade and demonstrate the functional relevance of the 
pathway in osteoclast differentiation. Of translational 
relevance, antagonizing miR-218-5p in cancer cells 
strongly reduced Rankl expression in osteoblasts through 
PTHrP and perhaps other secreted factors, leading to 
inhibition of osteoclast differentiation in vitro and in 
vivo. Although approaches to replace or inhibit miRNAs 
have been investigated in the context of other tumors, 
only a limited number of miRNAs have been associated 
with breast cancer-induced osteolytic disease. Promising 
results have been obtained by targeting osteoclasts with 
miR-141 and miR-219 [44] or breast cancer cells with 
miR-135 and miR-203 [16]. Both approaches cause a 
reduction of the osteolytic disease. While these results 
provide encouraging support for the development of 
miRNA-based therapeutic interventions, both studies 
[16, 44] used miRNA replacement therapy. Repressing 
endogenous miRNA function using synthetic, sequence-
specific antisense miRNA-inhibitors (anti-miR) is a 
complementary and equally effective option for reducing 
tumor properties [45]. Our study establishes a novel anti-
miR-based approach to limit the osteomimetic properties 
of disseminated tumor cells and osteolytic disease, 
which can open new dimensions for the development of 




Tissue biopsies derived from primary breast cancer 
were purchased from Amsbio. Tissue biopsies from bone 
metastases of breast cancer patients and from healthy 
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age-matched women were obtained from the archives 
of the University Medical Center Hamburg-Eppendorf, 
Germany, following institutional guidelines. Tissue 
samples were evaluated independently by two expert 
pathologists. All studies using human samples were 
carried out in accordance with the declaration of Helsinki.
Cell culture
The human mammary epithelial cell line (ER-; 
MCF-10A) and the breast cancer cell lines MCF-7 (ER+) 
and MDA-MB-231-a (ER-; hereafter MDA-MB-231) 
were purchased from ATCC. The MDA-MB-231-b 
subclone was kindly provided by Dr. Theresa Guise. Both 
cell lines are highly metastatic triple negative (ER-, PR-, 
HER-) breast cancer cells. Generation and characterization 
of the ER- MCF-10A-derived pre-malignant MCF-10AT1 
and malignant MCF10CA1a cell lines has been previously 
described [21, 22].
MCF-10A cells were cultured in MEGM medium 
(Lonza) supplemented with 100 ng/ml cholera toxin. 
MCF-7 cells were maintained in D-MEM (high Glucose) 
(Lonza) supplemented with 10% Fetal Bovine Serum 
(FBS, Atlanta) and 1% Penicillin/Streptomycin (Gibco). 
MDA-MB-231 cells were cultured in alpha-MEM 
(Lonza), 10% FBS and 1% Penicillin/Streptomycin. All 
cell lines were validated at the Vermont Cancer Center 
DNA Analysis Facility by STR DNA fingerprinting 
using the Promega GenePrint® 10 System according to 
manufacturer's instructions (Promega #B9510). The STR 
profiles were compared to known ATCC fingerprints 
(ATCC.org), and to the Cell Line Integrated Molecular 
Authentication database (CLIMA) version 0.1.200808 
(http://bioinformatics.istge.it/clima) [23]. The STR 
profiles of all cell lines matched (>85%) known DNA 
fingerprints. To inhibit Wnt signaling MDA-MB-231 
cells were treated with 30 μM small molecule inhibitor 
CCT036477 (Enzo Life Sciences) [24]. To activate Wnt 
signaling, cells were incubated with lithium chloride 
(LiCl) solution (Sigma-Aldrich) at a final concentration of 
40 mM [25]. To collect conditioned medium (CM), MDA-
MB-231 cells were seeded at 80% confluence in complete 
medium. Cells were serum starved for 24 h in 2% FBS 
prior collection of the CM. CM was centrifuged to remove 
cell debris and used immediately or stored at -80 °C.
Long bone osteoblasts were isolated from the 
femora and tibiae of 8-10-week old wild type C57/
Bl6 mice. After removing the muscles in sterile PBS, 
bone marrow was flushed out and bones were cut 
into small pieces. Bone pieces were digested with 
0.1% collagenase for 2 hours at 37°C and plated in 
α-MEM containing 10% FBS and 1% P/S. Outgrowing 
osteoblasts were trypsinized after one week and cultured 
until confluence (2-3 weeks). Bone marrow macrophages 
(BMMs) were isolated from the bone marrow of 8-week 
old wild type mice. Non-adherent cells were collected 
after 3 hours of incubation on plastic and cultured with 
Macrophage colony-stimulating factor (MCS-F; 100 ng/
ml, Peprotech). For osteoblast-osteoclast co-cultures, 
long bone osteoblasts were plated on 96-well plates and 
stimulated with Vitamin D3 and prostaglandin E. One 
day later, BMMs were plated over osteoblasts. Cultures 
were terminated after 5 days, fixed and stained with 
Tartrate-resistant acid phosphatase (TRAP) for 10 min 
at 37°C. All reagents for TRAP solution (Naphthol-
ASMX-Phosphate, Fast Red Violet LB-Salt and N,N-
Dimethylformamid) were purchased from Sigma. 
TRAP-positive cells with a minimum of three nuclei 
were considered as osteoclasts and counted using the 
Osteomeasure system (Osteometrics).
Immunohistochemistry
Human tissue biopsies and mouse bones and 
lungs were fixed in 4% Formalin/PBS. Bones were 
decalcified in 4% Na-EDTA solution at pH 7.4 for 2 
weeks. Tissues were dehydrated, embedded in paraffin 
and cut. Consecutive 4 μm thick sections were analyzed 
by immunohistochemistry using antibodies against 
β-Catenin (Cell Signaling), Ki-67 (Dako), PTHrP (Cell 
Signaling) and HLA class 1 ABC (Abcam) with positive 
and negative controls following established protocols [26]. 
Antigen retrieval was performed using citrate buffer at pH 
6.0. Vectastain (Vector Laboratories) and DAB+ (Dako) 
systems were used for detection. TRAP solution was 
prepared as described and sections were stained for 10 min 
at 37°C. Ki-67-positive cells in bones and HLA-positive 
metastatic nodules in mouse lungs were quantified using 
the Osteomeasure system.
Transfections
MDA-MB-231 cells were plated in 6-well 
plates and transfected at 70-80% confluence with 
mirVana™ miRNA mimics and inhibitors (Ambion) 
at a final concentration of 50 nM in OPTI-MEM using 
Oligofectamine Reagent (Invitrogen) according to 
manufacturer’s instructions. Fresh culture medium 
containing 20% FBS was added after 4 h. Cells were 
used for functional studies or harvested for RNA and 
protein analyses as described.
For the 3’ UTR assays, the 3’UTRs of SOST and 
SFRP2 were cloned into a pMIR-Reporter Luciferase 
Plasmid (Applied Biosystems) to obtain Luc-SOST-
3’UTR and Luc-SFRP2-3’UTR reporter plasmids 
[20]. Cells were transfected with miRNA mimic and 
inhibitor oligonucleotides using oligofectamine as 
described above. On the following day, cells were 
transfected with 500 ng of 3’UTR plasmids each 
along with 50 ng Renilla luciferase plasmid (Promega) 
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using Xtremegene9 (Roche) following manufacturer’s 
instructions. Luciferase assays were performed using the 
Dual Luciferase Reporter Gene Assay System (Promega) 
according to instructions provided by the manufacturer. 
Lentivirus clones control (PMIRH000PA-1), 
miRNA-218 (PMIRH218-2PA-1) and anti-miR 
Lentivirus (miRZip-218 anti-miR, MZIP218-PA-1) 
were purchased from System Biosciences and infected 
as described previously [27].
Total RNA extraction and gene expression 
analysis
Total RNA was isolated using Trizol reagent 
(Invitrogen) and purified with Zymo RNA purification kit 
(Zymo) according to manufacturer’s instructions. cDNA 
was synthesized from 1 μg of total RNA using Supercript 
RT kit (Invitrogen) following the protocol provided by 
the manufacturer. Quantitative real-time PCR (qRT-
PCR) was performed with the 7300 sequence detection 
system (Applied Biosystems/Roche) using SYBR® Green 
Master Mix (Applied Biosystems). After normalization to 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
mRNA, relative expression levels and fold induction of 
each target gene were calculated using the comparative CT 
(ΔΔCT) method.
MiRNA extraction and expression analysis
Total RNA was isolated from cells and purified as 
described above. RNA extraction from paraffin embedded 
tissue samples was performed using the High Pure FFPE 
RNA Micro-kit (Roche) according to manufacturer’s 
instructions [26]. The QuantimiR-kit (SBI System 
Biosciences) was used to add a polyA tail to the small 
RNAs for cDNA synthesis (SBI System Biosciences) 
according to manufacturer’s guidelines. Relative miRNA 
expression was determined by SYBR Green detection 
(Applied Biosystems) using a universal reverse primer 
and a specific forward primer designed for miR-218-5p 
[20]. U6 expression was used as internal control. The 
relative miRNA expression was calculated using the 
ΔΔCT method.
ELISA
Conditioned medium was collected from MDA-
MB-231 cells transfected with miR-218-5p mimics and 
inhibitors as described above. PTHrP was quantified in the 
conditioned medium using ELISA (Lifespan Biosciences).
Proliferation assay
MDA-MB-231 cell proliferation was determined by 
the CellTiter MTS assay (Promega). Cells were seeded 
in 96-well plates at a density of 3000 cells/well before 
performing the MTS assay according to manufacturer’s 
instructions.
Migration assays
Cell migration was determined using a wound 
healing assay. For this purpose, MDA-MB-231 cells were 
plated in 6-well plates, transfected with miRNA mimics 
or inhibitors as described and cultured to 90-100% 
confluence. A wound was then applied with a pipette tip 
and closure of the wound was monitored by microscopy. 
The width of the wound was quantified using the ImageJ 
program.
Intratibial injection of miRNA-transfected 
breast cancer cells
All animal studies were conducted in accordance 
with approved Institutional Animal Care and Use 
Committee protocols following the ethical guidelines 
of the NIH Guide for the Care and Use of Laboratory 
Animals. Severe combined immunodeficient (SCID) 
mice were obtained from the Jackson Laboratory. MDA-
MB-231 cells stably expressing luciferase (MDA-MB-
231-luc) were transfected with miR-218-5p or antimiR-
218-5p and the control oligonucleotides as described. 
After 24 h, cells were counted and suspended in sterile 
PBS (100,000 cells/100 μl). Female SCID mice (6-week 
old) were anesthetized by intraperitoneal (i.p.) injection of 
Ketamine/Xylazine (Ketamine: 100 mg/kg body weight; 
Xylazine: 10mg/kg body weight). The knee of the right 
hind limb was flexed and a short incision was made over 
the knee. A 30-gauge needle on a tuberculin syringe was 
then inserted into the intramedullary space of the tibia, 
followed by the careful injection of 100 μl of MDA-MB-
231-luc cell suspension. A minimum of 6 mice were used 
per group.
Monitoring tumor growth and osteolysis
Bioluminescence imaging (Xenogen) was used to 
follow the tumor growth in the bone. For this purpose 
mice were anesthetized using isoflurane followed by 
the injection of D-luciferin (i.p.) at a dose of 150 mg/kg 
per body weight. The animals were placed on the warm 
(37°C) IVIS imaging stage and bioluminescent images 
were acquired for each mouse using the IVIS Imaging 
System (Perkin Elmer). Analyses were performed using 
the LivingImage software (Xenogen) by measuring the 
photon flux within a region of interest drawn around the 
bioluminescence signals. Blank regions of interest were 
also measured for each scan and subtracted from each 
tumor photon flux for normalization.
Tibiae were scanned in air aligned axially using a 
micro CT scanner (Scanco Medical μCT 40) at 70kVp, 
114μA and a resolution of 10μm.
Oncotarget79044www.impactjournals.com/oncotarget
miRNA target prediction and pathway analysis
Putative targets of miR-218-5p were identified in 
IPA (www.ingenuity.com, QIAGEN, Germantown, MD) 
using default parameters and restricted to downstream 
molecules within the miR-218-5p interaction network. 
Ingenuity canonical pathways related to osteogenesis were 
identified based on significant enrichment. miR-218-5p 
targeted genes were mapped onto these pathways.
Statistical analysis
Normal distribution of the data was tested using the 
D'Agostino-Pearson omnibus test. Comparisons between 
groups were analyzed using one-way ANOVA with 
Tukey’s post-hoc tests.
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